We would love to hear your thoughts about our site and services, please take our survey here.
..at the data available in tuuletusaukko osaketutka, it seems that during those Nasdaq highs late March-early April many offshore holders of the share made their exit and gave them to Finnish small investor hands, where they mostly lie today, still. This accounts the Lago capital switcharoos, also, but there have been others.
Nice info! Many movements make more sense to me now.
Doubt it, the prices are quite close.
This remains to be seen, thanks for the input.
No one would take partners ever, if they could do it by themselves. Regarding traumakine the situation has changed since 2018 through covid and Remap-cap. Not sure about clevegen, now that they got more money for those studies. Do they still need a partner for Clevegen?
I'm well aware of that. It is also a bit scary, if the big pharma's and the people behind the scenes would decide at some point that the rivalling treatments must fail also. I hope some of my bleak views never see the light of day. It is good that Faron has been so open with their results, it gives them protection as well as publicity.
Ridiculously big, if this would be the conclusion.
It would be f****** peachy to have your MOM in control of your research funding...
In very short, intracellular adenosine buildup inhibits breast cancer cells from multiplying (aka. forming a tumor).
I still don't understand how something like this is possible.
well, any REAL news anyway 8P
"657,237 Placing Shares (//reduced to 435500 as far as I understand) and, to the extent that the Broker Option is exercised, any Option Shares to be issued (comprising the "Third Issue Shares") are expected to be issued and registered on or about 28 April 2020. "
I wouldn't expect news before the next Tuesday.
How is something like this possible? Not so experienced in various big boy market shenanigans.
Absolutely, Sax. There is enough potential for the new evaluation of the sp to blow sky high. Still, if people start evaluating "Traumakine-vaccine" into the sp, they must be extremely careful and knowing in what they're doing.
Rick, point me a substance that doesn't work being put into a clinical trial phase IV. Healthy sceptisism is fine but please just look at the facts. It would be pretty outrageous if interferon beta a1 didn't work at this point, after so many billions several pharmaceutical companies have thrown at it during all these years. I get it, these are very unnerving times but please follow your strategy and wait out for the news or bail out. Don't post, if the only point is to lay your own insecurities out. This is not a therapeutic message board.
Investing is sometimes a minute game, sometimes a decade game; the fun things is that nobody really knows which it is until it has already passed. In the end we're all alone with our own money. While anyone is allowed to have differing opinions, especially on such fickle matters as stock market movements. Still, there are always some facts out there and in the case of Faron there are plenty of positive signs posted here so many times. If you differ in your opinion against such amount of evidence to the contrary.. you better have something backing your statement up. Otherwise it will look like deramping.
What the..? You must be pretty sad individual to come here gloating every second day when no great growth of the sp have happened -for the second- time just in few months. Even exactly now after MASSIVE RED DAYS (not) Faron sp is exactly 287% higher than 6 months before. We're waiting for the next round of news/results etc. while also keeping up with "the blood flow" to the mental image of our positive (for most at least) expectations. Get over it. I really don't know why I even bothered.
Great informative post Sax. The difference between our injectable interferon beta with earlier injectable forms used to treat MS symptoms is that of the injection itself. As Zen has mentioned a million times now our Inf-B is intravenous, and the others either subcutaneous (under the skin; fat usually) or muscle injections. The inhaled form by Synairgen is completely different approach. What I find interesting between our inf-B and Synairgen's inhaled one is that the dosages vary massively. We know that Faron uses 10 ug (micrograms) of active ingredient while SNG reports using 6 IU (international units) of active ingredient. This translates to regarding human recombinant inf-B 1a to massive dose of 1,68 mg (milligrams). According to this information, administering inf-B to lungs is much less effective through inhalation, or there's a possibility that Faron could be able to increase the dose with quite the amount, and reach effectiviness (maybe, it's not that simple in reality) levels of totally different calibre. Of course, as I said, in reality the connection is not this easy to make.
..guys, I'd like to turn the focus on the paper itself instead of the various personalities found interested in this company, at least so much to find themselves on this board. Zen's big reveal or not the earlier facts still stand. 1) We are waiting for news of Clevegen's partner (+?); 2) Traumakine is in the huge trial REMAP-CAP, which pretty much overrides the need of that lingering trial III (+); 3) Traumakine's functionality is the same as it always was, you either believe the post hoc analysis of the previous trial III or not; most do. If you do, then does this not bring us pretty close to the situation 2018 when the paper was valued 8£ (and that's disregarding all else, e.g. "secret weapon")? (+, if the trial failure was an error); [4) If you believe that Traumakine works, the market potential is quite large, and Faron has the upper hand over upcoming rivals with the protected dosing/lyophilization perks (+++)]. So, take your guess with the price among all the others, but please keep the discussion fruitful and focused on the company/stock itself. If you absolutely abhor some of the posters' input here, please use the "hide" feature.
That is quite significant indeed